Skip to main content

Technology@Intel

Technology@Intel

Thunderbolt™ 3 is Gaining Momentum

Posted: 17 Aug 2015 08:35 AM PDT

Note: this is reposted from the Thunderbolt Community site

In June at Computex 2015, Intel unveiled Thunderbolt™ 3 – The USB-C that does it all.  Since then, we've seen a lot of excitement in the press and industry about Thunderbolt 3.  Thunderbolt 3 brings Thunderbolt™ to USB-C at speeds up to 40 Gbps, creating one compact port that does it all – delivering the fastest#, most versatile connection to any dock, display, or data device##.  For the first time, one computer port connects to Thunderbolt™ devices, every display, and billions of USB devices.  A Thunderbolt 3 cable provides four times the data transfer per second and twice the video bandwidth of any other cable, while also supplying power.  It's unrivaled for new uses, such as 4K video, single-cable docks with charging, external graphics, and built-in 10 GbE networking.

 

big-picture-with-text_update

Image 1:  The four capability vectors for Thunderbolt 3

Today Intel proudly announced the USB 3.1 certification of the Intel® Thunderbolt™ 3 controller and is among the first to pass this level of acceptability set forth by the USB-IF industry group's compliance program.  Thunderbolt 3 controllers provide two ports that include USB 3.1 support with dedicated bandwidth of 10 Gbps each, instead of shared, providing more bandwidth than other USB controllers#.

In recent news, Intel announced the new Intel® Xeon processors and Lenovo* announced their new family of mobile workstations, the ThinkPad P50 and P70, based on Intel® Xeon® Processor E3-1500M v5 product family and features two Thunderbolt 3 ports for ultra-fast connectivity and a 4K UHD display or optional FHD touch.

Lenovo ports

Image 2:  Lenovo ThinkPad P70 with its two Thunderbolt 3 ports

At IDF15, taking place in San Francisco August 18-20, several Thunderbolt demos will be on display in the Thunderbolt Community, booth numbers 931-942, with a dozen of our partners.  A Thunderbolt 3 single-cable docking demo will also be highlighted in this area.  And don't miss the Thunderbolt 3 external graphics demo in the Computing Innovation Zone.  This is the first event where Thunderbolt 3 demos will be showcased publicly!  For those interested in storage, by utilizing Thunderbolt 3 in tandem with the Intel® SSD 750 Series, we've created an external storage enclosure capable of running the 750 SSD at full performance – come check it out at booth number 570.  Not to mention, there will be Thunderbolt 3 Tech Chats on Tuesday, August 18 from 1-3 p.m. and again on Wednesday, August 19 from 1-3 p.m., if you'd like to learn more.  Lastly, there will be a Thunderbolt 3 session on Thursday, August 20th in room 2006 from 10:45 – 11:45 a.m.  Please check out all that Thunderbolt has to offer at IDF this year!

#  As compared to other PC I/O connection technologies including eSATA, USB, and IEEE 1394 Firewire.  Performance will vary depending on the specific hardware and    software used.  Must use a Thunderbolt-enabled device.
## Thunderbolt 3 provides DisplayPort*, which can natively connect to all displays with DisplayPort and mini-DisplayPort*, and via adapters can connect to all other modem display interfaces, including HDMI, DVI, and VGA.
Tests document performance of components on a particular test, in specific systems. Differences in hardware, software, or configuration will affect actual performance. Consult other sources of information to evaluate performance as you consider your purchase.  For more complete information about performance and benchmark results, visit http://www.intel.com/performance
Intel, the Intel logo, Thunderbolt and the Thunderbolt logo are trademarks of Intel Corporation in the United States and other countries.
*  Other names and brands may be claimed as the property of others.

The post Thunderbolt™ 3 is Gaining Momentum appeared first on Technology@Intel.

Comments

Post a Comment

Popular posts from this blog

The first drug for a common, deadly liver disease is here – and more are coming

VIEW IN BROWSER | SUBSCRIBE TUE, MAR 19, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good morning!  Millions of Americans with a common and potentially life-threatening form of liver disease will soon have access to the first-ever treatment for the condition.    In a landmark decision on Thursday, the Food and Drug Administration approved Madrigal Pharmaceuticals ' drug " Rezdiffra ," to be used along with diet and exercise. The company expects the medicine to be available next month with a hefty price tag of $47,400 per year before insurance and other rebates.    So, why is this approval so important?    First of all, people suffering from the disease badly need a treatment. Rezdiffra is specifically approved to treat patients with nonalcoholic steatoh
Post a Comment
Read More

J&J, Merck and Bristol Myers Squibb are in the hot seat

VIEW IN BROWSER | SUBSCRIBE TUE, JAN 30, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up.   Good afternoon! This is Annika Kim Constantino, and I cover the biotech and pharmaceutical industry for CNBC.com .    Three names in the industry – Johnson & Johnson, Merck and Bristol Myers Squibb – face a pivotal few weeks ahead.    CEOs from those companies are slated to testify at a Senate hearing on high prescription drug prices in the U.S. on Feb. 8 at 10 a.m. ET, Sen. Bernie Sanders announced Friday.   It took subpoena threats from the senator, but J&J CEO Joaquin Duato and Merck CEO Robert Davis have agreed to testify after both executives declined earlier requests to appear at the Senate HELP committee's hearing. They join Bristol Myers Squibb CEO Chris Boerner, who agr
Post a Comment
Read More

How competitive can Roche be in the weight loss drug market?

VIEW IN BROWSER | SUBSCRIBE TUE, SEP 17, 2024 EDITOR'S NOTE     Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon!  Roche is one of several drugmakers hoping to join the booming weight loss drug market, which Novo Nordisk and Eli Lilly are currently dominating. But can the Swiss company develop drugs that can compete with that duopoly?  The answer isn't clear yet.  We need to see more data from longer and larger clinical trials, which will likely take years for Roche to conduct.  But the company last week presented more early-stage data more early-stage data on its experimental obesity injection and pill, which some analysts said raised concerns about how competitive those products can be if they enter the space. Some analysts said the new results showed that both drugs – which Roche acquired through its nearly $3 billion acquisition of Carmot Therapeutics in December – caused a higher rate of side
Post a Comment
Read More